Company News

Share this article:

Sanofi-Aventis will acquire California-based BiPar Sciences for up to $500 million. BiPar Sciences is a pharma focused on a novel cancer treatment, known as BSI-201. The acquisition is the third this month for Sanofi – the company purchased Medley, a Brazillian generics manufacturer, and Laboratorious Kendrick, a Mexican generic company.

 

Johnson & Johnson announced that it will shift its wellness and disease-prevention business under the consumer business umbrella. J&J had initially planned to develop a separate wellness and disease-prevention business, with the acquisition of Michigan-based HealthMedia, according to a Wall Street Journal report.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.